Real-world Study of Pyrotinib-containing Regimens of Advanced HER2-positive Breast Cancer

Given that pyrotinib has been proven to exert significant efficacy against HER2-positive advanced breast cancer in multiple Phase III studies, and the novel ADC drug disitamab vedotin has demonstrated potent anti-tumor activity, there remains insufficient real-world data on their sequential administration. This multicenter, prospective real-world study plans to enroll 500 patients with HER2-positive advanced breast cancer receiving first-line or second-line treatment. It aims to evaluate the efficacy and safety of sequential disitamab vedotin treatment after disease progression or intolerance

Trial Details

NCT ID
NCT07600164
Phase
PHASE4
Sponsor
Peking University People's Hospital
Status
RECRUITING
Cancer Type
HER2 Negative Breast Cancer
Interventions
  • Pyrotinib
  • Trastuzumab Rezetecan
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • Aged ≥ 18 years old;
  • Histopathologically confirmed HER2-positive inoperable locally advanced or metastatic breast cancer;
  • Patients with first-line or second-line advanced disease:
  • First-line advanced disease: no prior systemic therapy for locally advanced or metastatic disease. For patients who received neoadjuvant or adjuvan…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Negative Breast Cancer Trials on Trialify →